Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Biotechnology

Healthcare
$27.61 -1.93%

-$0.51 today

Market cap
$3.49B
Beta
1.52
P/E (TTM)
-1400.0
EPS (TTM)
-$0.02
52W Low $13.06High $31.77

Volume 0.84M

Average 1.61M

ARQT Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense declines year over year

Q2 FY2026 income tax expense of $136K fell 60.2% year over year, behind the -17.5% change in trailing-twelve-month income tax expense. Sequentially, it rose 46.2% from the prior quarter.

Context

  • Income tax expense amounted to 0.3% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -60.2% toward the trailing-twelve-month pace of -17.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$136K+46.2% QoQ
Last fiscal yearDec 2025
$1.17M+81.0% YoY
LTMJun 2026
$779K-17.5% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-60.2%——
1 year+81.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
1.17M USD
Year-over-year change
+81.0%

Income Tax Expense vs competitors

How ARQT compares with its peers on the latest reported figures

  • ARQT's LTM Jun 2026 income tax expense of $779K is the highest of the 6 companies compared; the peer median is $0.
  • Income tax expense amounts to 0.2% of revenue for ARQT, versus a peer median of 0.0%.
ARQT Competitors Peer median
Income Tax Expense for ARQT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$779K -17.5%—0.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
TTRXTurn Therapeutics Inc.LTM Mar 2026$0 ———
EVMNEvommune, Inc.LTM Mar 2026$0 ——0.0%
SLGLSol-Gel Technologies Ltd.LTM Mar 2026$0 ——0.0%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding ARQT) $0——0.0%

Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.69M59.61M196.54M376.07M
Cost of Revenue763K754K4.99M19.13M36.7M
Gross Profit(763K)2.93M54.62M177.41M339.38M
Gross Margin—79.5%91.6%90.3%90.2%
Research & Development145.56M182.44M110.58M76.42M77.05M
Selling, General & Admin60.97M122.12M185.15M229.39M274.55M
Operating Expenses205.77M304.56M295.72M305.81M351.6M
Depreciation & Amortization454K934K750K2.6M4.67M
EBITDA(205.9M)(294.87M)(228.57M)(109.63M)1.78M
EBITDA Margin—-7999.8%-383.5%-55.8%0.5%
Operating Income(206.53M)(301.63M)(241.1M)(128.4M)(12.23M)
Operating Margin—-8183.0%-404.5%-65.3%-3.3%
Interest Income173K0000
Interest Expense015.65M29.71M27.17M12.08M
Other Income / Expenses173K(9.83M)(17.93M)(11M)(2.74M)
Income Before Tax(206.36M)(311.46M)(259.03M)(139.39M)(14.97M)
Pre-Tax Margin—-8449.8%-434.6%-70.9%-4.0%
Income Tax Expense003.11M647K1.17M
Net Income(206.36M)(311.46M)(262.14M)(140.04M)(16.14M)
Net Margin—-8449.8%-439.8%-71.3%-4.3%
EPS (Basic)(4.17)(5.66)(3.78)(1.16)(0.13)
EPS (Diluted)(4.17)(5.66)(3.78)(1.16)(0.13)
Weighted Avg Shares49.41M55.03M69.31M120.96M127.23M
Weighted Avg Shares (Diluted)49.41M55.03M69.31M120.96M127.23M

Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Intrinsic Alpha fair value

Locked

Current Price

$27.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.